State Street’s Elevation Oncology ELEV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-194,800
| Closed | -$71.5K | – | 4313 |
|
|
2025
Q2 | $71.5K | Sell |
194,800
-861,517
| -82% | -$288K | ﹤0.01% | 4034 |
|
|
2025
Q1 | $274K | Sell |
1,056,317
-15,566
| -1% | -$8.89K | ﹤0.01% | 3750 |
|
|
2024
Q4 | $603K | Buy |
1,071,883
+53,857
| +5% | +$31.8K | ﹤0.01% | 3582 |
|
|
2024
Q3 | $611K | Buy |
1,018,026
+120,993
| +13% | +$179K | ﹤0.01% | 3561 |
|
|
2024
Q2 | $2.42M | Buy |
897,033
+786,433
| +711% | +$2.96M | ﹤0.01% | 3244 |
|
|
2024
Q1 | $567K | Buy |
110,600
+68,500
| +163% | +$222K | ﹤0.01% | 3614 |
|
|
2023
Q4 | $22.6K | Hold |
42,100
| – | – | ﹤0.01% | 4329 |
|
|
2023
Q3 | $27.9K | Hold |
42,100
| – | – | ﹤0.01% | 4400 |
|
|
2023
Q2 | $64K | Hold |
42,100
| – | – | ﹤0.01% | 4350 |
|
|
2023
Q1 | $80K | Buy |
42,100
+23,600
| +128% | +$30.5K | ﹤0.01% | 4390 |
|
|
2022
Q4 | $17.5K | Hold |
18,500
| – | – | ﹤0.01% | 4758 |
|
|
2022
Q3 | $21K | Hold |
18,500
| – | – | ﹤0.01% | 4825 |
|
|
2022
Q2 | $26K | Hold |
18,500
| – | – | ﹤0.01% | 4837 |
|
|
2022
Q1 | $47K | Hold |
18,500
| – | – | ﹤0.01% | 4803 |
|
|
2021
Q4 | $111K | Hold |
18,500
| – | – | ﹤0.01% | 4554 |
|
|
2021
Q3 | $144K | Buy |
+18,500
| New | +$200K | ﹤0.01% | 4462 |
|
Other funds holding ELEV
State Street's ELEV Position: Q3 2025 in Review
State Street sold out of Elevation Oncology (ELEV) in Q3 2025, closing a stake of 194,800 shares — an estimated $71.5K sold.
State Street first reported a position in ELEV in Q3 2021 and held it in 16 quarters. The position peaked at $2.42M in Q2 2024. 1 fund tracked by Wall St. Rank holds ELEV as of Q3 2025.
- State Street reported no remaining Elevation Oncology position as of Q3 2025 after selling out during the quarter.
- State Street sold 194,800 Elevation Oncology shares in Q3 2025, an estimated $71.5K.
- State Street first reported a position in Elevation Oncology in Q3 2021 and held it in 16 quarters.
- State Street's Elevation Oncology position peaked at $2.42M in Q2 2024.
- 1 fund tracked by Wall St. Rank held Elevation Oncology as of Q3 2025.
Based on State Street's 13F filing for Q3 2025, filed 14 Nov 2025.